You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 12094 results
  1. Asylon Automated Robotics for Automated Perimeter Security

    SBC: ASYLON INC            Topic: AF20RDCSO1

    During this 48-month period of performance, Asylon, Inc. (“Asylon”) will complete the RDT&E necessary to refine the DroneCore platform to the point of scalable deployment across AFGSC and the DAF. Asylon has broken this development into several different

    SBIR Phase II 2023 Department of DefenseAir Force
  2. X-Hab Reef: Sustainable Carbon-Neutral Materials for 3D-Printable Coastal Infrastructure

    SBC: X-HAB 3D, INC.            Topic: HR0011SB2022401

    We propose to engage in a parallel, two-track approach for Phase II in order to expedite the availability of Reefense artificial reefs to protect DoD’s coastal facilities. Track 1 of this approach will initially use our 3D Concrete Printing (“3DCP”) system and traditional concrete mixtures modified to sequester carbon, to 3D print the novel reef structures designed by the Applied Research La ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  3. Boron-containing antimalarial drug discovery

    SBC: REACTIVE BIOSCIENCES INC            Topic: NIAID

    PROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Digital Uroflowmetry for Office and Home

    SBC: UROGENIE LLC            Topic: 400

    Abstract Uroflowmetry is the most common urodynamic test performed by urologists to assess the function of the lower urinary tract. This simple non-invasive study measures urinary flow rates and when summarized graphically offers insights into various types of lower urinary tract symptoms. Current systems call upon a patient to void into a commode with a funnel to direct the flow of urine into a v ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Dynamic Evaluation of Hypersonic Missile Debris Penetration

    SBC: CORVID TECHNOLOGIES, LLC            Topic: N161019

    Non-warhead debris from a typical anti-ship or air-to-air missile can comprise as much as 70% of the total striking mass, which makes it a crucial component of any lethality or survivability assessment and increasingly important as stand-off missile programs are rising in demand.  Many current LVS modeling tools in use by the government do not address residual non-warhead missile debris at all, a ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  6. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea

    SBC: AIMMAX THERAPEUTICS INC            Topic: NIAID

    PROJECT SUMMARY / ABSTRACT The CDC has identified Neisseria gonorrhoeae as a pathogen of the highest threat level (“Urgent Threat”) to the US public health. Currently there is only a single recommended agent remaining on the CDC treatment guidelines, an intramuscular injection of the extended spectrum cephalosporin, ceftriaxone. However, in the past decade, reports of resistance to ceftriaxone ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Commercializing CivaSheet for Pancreatic Cancer Patients

    SBC: CIVATECH ONCOLOGY INC            Topic: NCI

    CivaTech Oncology’s mission is to provide improved radiation therapy directly to diseased tissues while sparing healthy tissues. With NIH/NCI SBIR support, the Company has eliminated local recurrence of disease in pancreatic cancer patients – a huge success. Pancreatic cancer is predicted to soon become the most commonly diagnosed cancer in the US and there are no significant, impactful therap ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes

    SBC: FREEFLOW MEDICAL DEVICES LLC            Topic: 400

    PROJECT SUMMARY Approximately 80% of patients beginning hemodialysis (HD) in the United States use a catheter at treatment initiation, and 18.6% of all HD patients were using a catheter in 2017. However, the HD catheters (HDC) used for longer-term dialysis in patients have a high complication rate because of infections and dysfunction, with a catheter dysfunction rate of 0.5–3.42 episodes/1000 c ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARYThe activity of chromatin-associating proteins (CAPs) is fundamental to regulation of gene expression. Elucidating CAP activity is central to understanding the regulatory mechanisms that drive cell biology, both in the context of health and disease, and to guide development of novel therapeutics. However, this work is not straightforward, as CAP activity is regulated by multiple fac ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government